- May 12, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Darzalex
Synonyms :
Daratumumab
Class :
Antineoplastics and Monoclonal Antibody
Dosage Forms & Strengths
Injectable solution for single-use vial
100mg per 5ml -20mg/ml
400mg per 20ml -20mg/ml
Combination with lenalidomide or pomalidomide and dexamethasone for monotherapy (4-week course):
for weeks 1-8, a dose of 16 mg per kg was IV weekly, a total of 8 doses
for weeks 9-24, a dose of 16 mg per kg given IV for every two weeks a total of 8 doses 1st dose every two-week dosing schedule assigned till week 9
from week 25 onwards till disease progression, a dose of 16 mg per kg given IV every four weeks 1st dose every 4-week dosing schedule given till week 25
Combination with bortezomib, melphalan, and prednisone 6-week cycle:
for weeks 1-8, a dose of 16 mg per kg IV weekly, a total of 6 doses
for weeks 7-54, a dose of 16 mg per kg given IV every three weeks a total of 16 doses 1st dose every 3-week dosing schedule assigned till week 7
from week 55 onwards until disease progression, a dose of 16 mg per kg given IV every four weeks 1st dose every-4-week dosing schedule assigned till Week 55
Combination with bortezomib, thalidomide, and dexamethasone 4-week cycle:
for weeks 1-8, a dose of 16 mg per kg IV weekly, a total of 8 doses
for weeks 9-16, a dose of 16 mg per kg given IV for every two weeks a total of 4 doses 1st dose every 2-week dosing schedule assigned till week 9
Stop high dose chemotherapy and ASCT:
consolidation:
for weeks 1-8, a dose of 16 mg per kg is given IV for every two weeks 1st dose every 2-week dosing schedule is given at week one
Combination with bortezomib and dexamethasone 3-week cycle:
for weeks 1-9, a dose of 16 mg per kg IV weekly, a total of 9 doses
for weeks 10-24, a dose of 16 mg per kg given IV every three weeks a total of 5 doses 1st dose every-3-week dosing schedule given till week 10
from week 25 onwards until disease progression, a dose of 16 mg per kg IV every four weeks and 1st dose every-4-week dosing schedule given till week 25
Combination of carfilzomib and dexamethasone 4-week cycle:
for week one, a dose of 8 mg per kg IV on days 1 and 2, a total of 2 doses
for weeks 2-8, a dose of 16 mg per kg IV weekly, a total of 7 doses
for weeks 9-24, a dose of 16 mg/kg IV every two weeks, a total of 8 doses, and 1st dose every-2-week dosing schedule is given till Week 9
from week 25 onwards until disease progression, a dose of 16 mg per kg
every four weeks and 1st doses every-4-week dosing schedule till Week 25
may increase the risk of toxic effects when combined
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of severe and potentially fatal infections
when both drugs are combined, there may be an increased risk of developing a disease from the vaccine
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be reduced levels of white blood cell count
when both drugs are combined, there may be reduced levels of white blood cell count
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
when both drugs are combined, there may be an increased risk of severe life-threatening infections
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
when both drugs are combined, there may be an increased risk of severe life-threatening infections
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be a decreased blood levels and effects of daratumumab
when both drugs are combined, there may be an increased risk of kidney damage
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of serious infections
when both drugs are combined, there may be an increased risk of kidney damage
when both drugs are combined, there may be an increased risk or severity of adverse effects
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
It may enhance the risk of adverse effects when combined with vitamins
It may enhance the adverse effects when combined with sotrovimab
Adverse drug reactions:
Frequency defined
>10%
Hypertension
Nausea
diarrhea
constipation
Vomiting
Lymphopenia
neutropenia
thrombocytopenia
Anemia
Infusion reaction
Decreased appetite
Back pain
Arthralgia
Pain in extremity
Musculoskeletal chest pain
1-10%
Pneumonia
Herpes zoster reactivation
Bronchospasm
Dyspnea
Hypoxia
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Daratumumab is a kind of monoclonal antibody that helps in retarding the growth of tumor cells by binding to a specific protein inside the body.
It treats bone marrow cancer or multiple myeloma. It is a steroid medicine.
If you need a blood transfusion during the treatment, inform your caregivers.
Daratumumab is harmful to the ingrowing fetus. Inform your physician if you are gestating or planning to conceive.
The pregnancy should be planned three months after the last dose of daratumumab.
Both men and women should opt for effective birth control methods during the treatment.
It is unsafe to take this drug during lactation.
If you miss a dose, tell your healthcare professional to reschedule it.
The side effects occurring after taking medicine include nausea, headache, dizziness, itchiness, runny or stuffy nose, fevers, cough, chills, throat tightness, or trouble breathing. If any of the side effects worsen, immediately contact your physician.
Store the medication at a cool temperature.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
